DE60227058D1 - - Google Patents
Info
- Publication number
- DE60227058D1 DE60227058D1 DE60227058T DE60227058T DE60227058D1 DE 60227058 D1 DE60227058 D1 DE 60227058D1 DE 60227058 T DE60227058 T DE 60227058T DE 60227058 T DE60227058 T DE 60227058T DE 60227058 D1 DE60227058 D1 DE 60227058D1
- Authority
- DE
- Germany
- Prior art keywords
- frk
- tyrosine kinase
- relates
- inhibitor
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000892986 Homo sapiens Tyrosine-protein kinase FRK Proteins 0.000 abstract 5
- 102100040959 Tyrosine-protein kinase FRK Human genes 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 101100227720 Mus musculus Frk gene Proteins 0.000 abstract 1
- 101000994660 Rattus norvegicus Potassium voltage-gated channel subfamily A member 2 Proteins 0.000 abstract 1
- 101710089880 Tyrosine-protein kinase FRK Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101230A SE0101230L (sv) | 2001-04-06 | 2001-04-06 | Ny användning av en tyrosinkinasinhibitor |
| PCT/SE2002/000682 WO2002080894A1 (en) | 2001-04-06 | 2002-04-05 | Novel use of tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60227058D1 true DE60227058D1 (de) | 2008-07-24 |
Family
ID=20283697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60227058T Expired - Fee Related DE60227058D1 (de) | 2001-04-06 | 2002-04-05 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040171563A1 (de) |
| EP (1) | EP1372621B1 (de) |
| AT (1) | ATE397921T1 (de) |
| DE (1) | DE60227058D1 (de) |
| DK (1) | DK1372621T3 (de) |
| SE (1) | SE0101230L (de) |
| WO (1) | WO2002080894A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| BR0212435A (pt) * | 2001-09-10 | 2004-08-17 | Sugen Inc | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase |
-
2001
- 2001-04-06 SE SE0101230A patent/SE0101230L/ not_active Application Discontinuation
-
2002
- 2002-04-05 WO PCT/SE2002/000682 patent/WO2002080894A1/en not_active Application Discontinuation
- 2002-04-05 DK DK02720710T patent/DK1372621T3/da active
- 2002-04-05 DE DE60227058T patent/DE60227058D1/de not_active Expired - Fee Related
- 2002-04-05 EP EP02720710A patent/EP1372621B1/de not_active Expired - Lifetime
- 2002-04-05 AT AT02720710T patent/ATE397921T1/de not_active IP Right Cessation
- 2002-04-05 US US10/473,765 patent/US20040171563A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SE0101230L (sv) | 2002-10-07 |
| WO2002080894A1 (en) | 2002-10-17 |
| EP1372621A1 (de) | 2004-01-02 |
| EP1372621B1 (de) | 2008-06-11 |
| SE0101230D0 (sv) | 2001-04-06 |
| ATE397921T1 (de) | 2008-07-15 |
| US20040171563A1 (en) | 2004-09-02 |
| DK1372621T3 (da) | 2008-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY152172A (en) | Therapeutic agent for diabetes | |
| PT1928499E (pt) | Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos | |
| MX2010001784A (es) | Activadores novedosos de la glucocinasa. | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| TW200745037A (en) | Organic compounds | |
| UA88257C2 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ С-α ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ПОЧЕК, КОТОРЫЕ ПРИВОДЯТ К ПРОТЕИНУРИИ, И ДИАБЕТИЧЕСКИМ РЕТИНОПАТИИ, НЕВРОПАТИИ ИЛИ НЕФРОПАТИИ | |
| MXPA04003759A (es) | Derivados de pirrolidin n-substituido como inhibidores de dipeptidil peptidasa iv. | |
| HUP0402403A2 (hu) | Cukorbetegség-ellenes hatású dipeptilpeptidáz IV (DP-IV) inhibitorok ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| MY127961A (en) | Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes | |
| DE60110054D1 (en) | Cardioprotektive phosphonate | |
| IS7753A (is) | Beta-amínó heterósýklískir dípeptidýl peptíðasa hindrar til meðhöndlunar á, eða til að fyrirbyggja,sykursýki | |
| EP1385508A4 (de) | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes | |
| WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
| EA200801538A1 (ru) | Лечение диабета 2 типа комбинацией ингибитора дипептидилпептидазы iv (dpiv) и метформина или тиазолидиндиона | |
| EP1490335A4 (de) | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes | |
| IS6329A (is) | Lyf til að meðhöndla illkynja æxli | |
| Baranov et al. | Feedback suppression of meal‐induced glucagon‐like peptide‐1 (GLP‐1) secretion mediated through elevations in intact GLP‐1 caused by dipeptidyl peptidase‐4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment | |
| DE60227058D1 (de) | ||
| Kalra et al. | Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications | |
| AP2004003113A0 (en) | Use of an inhibitor or antagonist against tissue factor | |
| WO2003099318A3 (en) | Pancreas-specific proteins | |
| MX2022011129A (es) | Composicion farmaceutica para la prevencion o el tratamiento de la diabetes y de enfermedades metabolicas asociadas a la misma. | |
| EP1813289A4 (de) | Medizinische zusammensetzung zur behandlung von krebs oder diabetes | |
| WO2004053107A3 (en) | Methods for treating diabetes | |
| TW200608967A (en) | Pharmaceutical compositions containing with diabetic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |